Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study.
about
Looking into the crystal ball-upcoming drugs for dyslipidemia.Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.Homozygous familial hypercholesterolaemia: update on management.Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.
P2860
Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Defining the Safety of Anacetr ...... art Disease: the DEFINE study.
@en
Defining the Safety of Anacetr ...... art Disease: the DEFINE study.
@nl
type
label
Defining the Safety of Anacetr ...... art Disease: the DEFINE study.
@en
Defining the Safety of Anacetr ...... art Disease: the DEFINE study.
@nl
prefLabel
Defining the Safety of Anacetr ...... art Disease: the DEFINE study.
@en
Defining the Safety of Anacetr ...... art Disease: the DEFINE study.
@nl
P2860
P1476
Defining the Safety of Anacetr ...... art Disease: the DEFINE study.
@en
P2860
P2888
P304
P356
10.1007/S12170-011-0159-3
P50
P577
2011-04-01T00:00:00Z